Levonadifloxacin Explained
| Drug Name: | Levonadifloxacin |
| Tradename: | Emrok |
| Routes Of Administration: | Parenteral |
| Atc Prefix: | J01 |
| Atc Suffix: | MA24 |
| Legal Status: | Rx in India |
| Synonyms: | (S)-(-)-Nadifloxacin |
| Cas Number: | 154357-42-3 |
| Pubchem: | 9850038 |
| Unii: | 8WHH66L098 |
| Iupac Name: | (12S)-7-Fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.0<sup>5,13</sup>]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid |
| C: | 19 |
| H: | 21 |
| F: | 1 |
| N: | 2 |
| O: | 4 |
| Smiles: | C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O |
| Stdinchi: | InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)/t10-/m0/s1 |
| Stdinchikey: | JYJTVFIEFKZWCJ-JTQLQIEISA-N |
| Chebi: | 37908 |
| Chembl: | 190561 |
Levonadifloxacin (trade name Emrok) is an antibiotic drug of the fluoroquinolone class.[1] [2] Chemically, it is the (S)-enantiomer of the racemic drug nadifloxacin.
It is approved in India for the treatment of skin and soft tissue infections of Gram-positive bacteria.[3] It is also being studied for potential use against resistant strains of bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis.[4]
Levonadifloxacin has poor oral bioavailability. A prodrug of levonadifloxacin with high oral bioavailability, alalevonadifloxacin, has been developed to mitigate this problem.[5]
Notes and References
- Patel A, Sangle GV, Trivedi J, Shengule SA, Thorve D, Patil M, Deshmukh NJ, Choudhari B, Karade A, Gupta S, Bhagwat S, Patel M . Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model . Antimicrobial Agents and Chemotherapy . 64 . 5 . April 2020 . 32152077 . 7179645 . 10.1128/aac.00084-20 .
- Bakthavatchalam YD, Shankar A, Muniyasamy R, Peter JV, Marcus Z, Triplicane Dwarakanathan H, Gunasekaran K, Iyadurai R, Veeraraghavan B . Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital . The Journal of Antimicrobial Chemotherapy . 75 . 8 . 2156–2159 . August 2020 . 32361727 . 10.1093/jac/dkaa142 .
- Web site: Levonadifloxacin . AdisInsight . Springer Nature Switzerland AG .
- Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, Periasamy H, Yeole R, Deshpande PK, Bhavsar S, Bhatia A, Ahdal J, Jain R, Patel M . Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence . Drug Design, Development and Therapy . 13 . 4351–4365 . 2019 . 31920285 . 6935279 . 10.2147/DDDT.S229882 . free .
- Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M . Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection . Bioorganic & Medicinal Chemistry Letters . 54 . 128432 . December 2021 . 34757217 . 10.1016/j.bmcl.2021.128432 .
